Literature DB >> 32013845

The QSAR Paradigm in Fragment-Based Drug Discovery: From the Virtual Generation of Target Inhibitors to Multi-Scale Modeling.

Valeria V Kleandrova1, Alejandro Speck-Planche2.   

Abstract

Fragment-Based Drug Design (FBDD) has established itself as a promising approach in modern drug discovery, accelerating and improving lead optimization, while playing a crucial role in diminishing the high attrition rates at all stages in the drug development process. On the other hand, FBDD has benefited from the application of computational methodologies, where the models derived from the Quantitative Structure-Activity Relationships (QSAR) have become consolidated tools. This mini-review focuses on the evolution and main applications of the QSAR paradigm in the context of FBDD in the last five years. This report places particular emphasis on the QSAR models derived from fragment-based topological approaches to extract physicochemical and/or structural information, allowing to design potentially novel mono- or multi-target inhibitors from relatively large and heterogeneous databases. Here, we also discuss the need to apply multi-scale modeling, to exemplify how different datasets based on target inhibition can be simultaneously integrated and predicted together with other relevant endpoints such as the biological activity against non-biomolecular targets, as well as in vitro and in vivo toxicity and pharmacokinetic properties. In this context, seminal papers are briefly analyzed. As huge amounts of data continue to accumulate in the domains of the chemical, biological and biomedical sciences, it has become clear that drug discovery must be viewed as a multi-scale optimization process. An ideal multi-scale approach should integrate diverse chemical and biological data and also serve as a knowledge generator, enabling the design of potentially optimal chemicals that may become therapeutic agents. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Artificial neural network; FBDD; QSAR; docking; molecular fragment; multi-scale model; pseudo-linear equation

Mesh:

Substances:

Year:  2020        PMID: 32013845     DOI: 10.2174/1389557520666200204123156

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN: 1389-5575            Impact factor:   3.862


  6 in total

1.  Prediction of QcrB Inhibition as a Measure of Antitubercular Activity with Machine Learning Protocols.

Authors:  Afreen A Khan; Sannidhi S Poojary; Ketki K Bhave; Santosh R Nandan; Krishna R Iyer; Evans C Coutinho
Journal:  ACS Omega       Date:  2022-05-19

Review 2.  Therapeutic role of corticosteroids in COVID-19: a systematic review of registered clinical trials.

Authors:  Reshma Raju; Prajith V; Pratheeksha Sojan Biatris; Sam Johnson Udaya Chander J
Journal:  Futur J Pharm Sci       Date:  2021-03-17

3.  Chemoinformatics Studies on a Series of Imidazoles as Cruzain Inhibitors.

Authors:  Alex R Medeiros; Leonardo L G Ferreira; Mariana L de Souza; Celso de Oliveira Rezende Junior; Rocío Marisol Espinoza-Chávez; Luiz Carlos Dias; Adriano D Andricopulo
Journal:  Biomolecules       Date:  2021-04-15

Review 4.  Use of Artificial Intelligence and Machine Learning for Discovery of Drugs for Neglected Tropical Diseases.

Authors:  David A Winkler
Journal:  Front Chem       Date:  2021-03-15       Impact factor: 5.221

Review 5.  Schistosomiasis Drug Discovery in the Era of Automation and Artificial Intelligence.

Authors:  José T Moreira-Filho; Arthur C Silva; Rafael F Dantas; Barbara F Gomes; Lauro R Souza Neto; Jose Brandao-Neto; Raymond J Owens; Nicholas Furnham; Bruno J Neves; Floriano P Silva-Junior; Carolina H Andrade
Journal:  Front Immunol       Date:  2021-05-31       Impact factor: 7.561

6.  A systematic review on use of aminoquinolines for the therapeutic management of COVID-19: Efficacy, safety and clinical trials.

Authors:  Vaishali M Patil; Shipra Singhal; Neeraj Masand
Journal:  Life Sci       Date:  2020-05-11       Impact factor: 5.037

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.